ID   UBP7_HUMAN              Reviewed;        1102 AA.
AC   Q93009; A6NMY8; B7Z815; H0Y3G8;
DT   01-NOV-1997, integrated into UniProtKB/Swiss-Prot.
DT   04-NOV-2008, sequence version 2.
DT   10-MAY-2017, entry version 189.
DE   RecName: Full=Ubiquitin carboxyl-terminal hydrolase 7;
DE            EC=3.4.19.12 {ECO:0000269|PubMed:11923872, ECO:0000269|PubMed:12507430, ECO:0000269|PubMed:14506283, ECO:0000269|PubMed:15053880, ECO:0000269|PubMed:16964248, ECO:0000269|PubMed:18716620, ECO:0000269|PubMed:21745816};
DE   AltName: Full=Deubiquitinating enzyme 7;
DE   AltName: Full=Herpesvirus-associated ubiquitin-specific protease;
DE   AltName: Full=Ubiquitin thioesterase 7;
DE   AltName: Full=Ubiquitin-specific-processing protease 7;
GN   Name=USP7; Synonyms=HAUSP;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), PARTIAL PROTEIN SEQUENCE,
RP   CATALYTIC ACTIVITY, SUBCELLULAR LOCATION, AND INTERACTION WITH
RP   HERPESVIRUS 1 TRANS-ACTING TRANSCRIPTIONAL PROTEIN ICP0/VMW110.
RC   TISSUE=Mammary cancer;
RX   PubMed=9034339; DOI=10.1093/emboj/16.3.566;
RA   Everett R.D., Meredith M., Orr A., Cross A., Kathoria M.,
RA   Parkinson J.;
RT   "A novel ubiquitin-specific protease is dynamically associated with
RT   the PML nuclear domain and binds to a herpesvirus regulatory
RT   protein.";
RL   EMBO J. 16:566-577(1997).
RN   [2]
RP   ERRATUM.
RX   PubMed=9130697; DOI=10.1093/emboj/16.7.1519;
RA   Everett R.D., Meredith M., Orr A., Cross A., Kathoria M.,
RA   Parkinson J.;
RL   EMBO J. 16:1519-1530(1997).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3).
RC   TISSUE=Testis;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15616553; DOI=10.1038/nature03187;
RA   Martin J., Han C., Gordon L.A., Terry A., Prabhakar S., She X.,
RA   Xie G., Hellsten U., Chan Y.M., Altherr M., Couronne O., Aerts A.,
RA   Bajorek E., Black S., Blumer H., Branscomb E., Brown N.C., Bruno W.J.,
RA   Buckingham J.M., Callen D.F., Campbell C.S., Campbell M.L.,
RA   Campbell E.W., Caoile C., Challacombe J.F., Chasteen L.A.,
RA   Chertkov O., Chi H.C., Christensen M., Clark L.M., Cohn J.D.,
RA   Denys M., Detter J.C., Dickson M., Dimitrijevic-Bussod M., Escobar J.,
RA   Fawcett J.J., Flowers D., Fotopulos D., Glavina T., Gomez M.,
RA   Gonzales E., Goodstein D., Goodwin L.A., Grady D.L., Grigoriev I.,
RA   Groza M., Hammon N., Hawkins T., Haydu L., Hildebrand C.E., Huang W.,
RA   Israni S., Jett J., Jewett P.B., Kadner K., Kimball H., Kobayashi A.,
RA   Krawczyk M.-C., Leyba T., Longmire J.L., Lopez F., Lou Y., Lowry S.,
RA   Ludeman T., Manohar C.F., Mark G.A., McMurray K.L., Meincke L.J.,
RA   Morgan J., Moyzis R.K., Mundt M.O., Munk A.C., Nandkeshwar R.D.,
RA   Pitluck S., Pollard M., Predki P., Parson-Quintana B., Ramirez L.,
RA   Rash S., Retterer J., Ricke D.O., Robinson D.L., Rodriguez A.,
RA   Salamov A., Saunders E.H., Scott D., Shough T., Stallings R.L.,
RA   Stalvey M., Sutherland R.D., Tapia R., Tesmer J.G., Thayer N.,
RA   Thompson L.S., Tice H., Torney D.C., Tran-Gyamfi M., Tsai M.,
RA   Ulanovsky L.E., Ustaszewska A., Vo N., White P.S., Williams A.L.,
RA   Wills P.L., Wu J.-R., Wu K., Yang J., DeJong P., Bruce D.,
RA   Doggett N.A., Deaven L., Schmutz J., Grimwood J., Richardson P.,
RA   Rokhsar D.S., Eichler E.E., Gilna P., Lucas S.M., Myers R.M.,
RA   Rubin E.M., Pennacchio L.A.;
RT   "The sequence and analysis of duplication-rich human chromosome 16.";
RL   Nature 432:988-994(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 705-1102 (ISOFORM 1), SUBCELLULAR
RP   LOCATION, AND INTERACTION WITH ATXN1.
RX   PubMed=12093161; DOI=10.1006/mcne.2002.1103;
RA   Hong S., Kim S.J., Ka S., Choi I., Kang S.;
RT   "USP7, a ubiquitin-specific protease, interacts with ataxin-1, the
RT   SCA1 gene product.";
RL   Mol. Cell. Neurosci. 20:298-306(2002).
RN   [7]
RP   FUNCTION, CATALYTIC ACTIVITY, INTERACTION WITH TP53, MUTAGENESIS OF
RP   CYS-223, AND ACTIVE SITE.
RX   PubMed=11923872; DOI=10.1038/nature737;
RA   Li M., Chen D., Shiloh A., Luo J., Nikolaev A.Y., Qin J., Gu W.;
RT   "Deubiquitination of p53 by HAUSP is an important pathway for p53
RT   stabilization.";
RL   Nature 416:648-653(2002).
RN   [8]
RP   FUNCTION (MICROBIAL INFECTION), SUBUNIT, BIOPHYSICOCHEMICAL
RP   PROPERTIES, ENZYME REGULATION, INTERACTION WITH HERPESVIRUS 1
RP   TRANS-ACTING TRANSCRIPTIONAL PROTEIN ICP0/VMW110 AND EBV EBNA1
RP   (MICROBIAL INFECTION), AND REGION.
RX   PubMed=14506283; DOI=10.1074/jbc.M307200200;
RA   Holowaty M.N., Sheng Y., Nguyen T., Arrowsmith C., Frappier L.;
RT   "Protein interaction domains of the ubiquitin-specific protease,
RT   USP7/HAUSP.";
RL   J. Biol. Chem. 278:47753-47761(2003).
RN   [9]
RP   FUNCTION, CATALYTIC ACTIVITY, INTERACTION WITH MDM2, MUTAGENESIS OF
RP   CYS-223, AND ACTIVE SITE.
RX   PubMed=15053880; DOI=10.1016/S1097-2765(04)00157-1;
RA   Li M., Brooks C.L., Kon N., Gu W.;
RT   "A dynamic role of HAUSP in the p53-Mdm2 pathway.";
RL   Mol. Cell 13:879-886(2004).
RN   [10]
RP   FUNCTION (MICROBIAL INFECTION), UBIQUITINATION, AND INTERACTION WITH
RP   HERPESVIRUS 1 TRANS-ACTING TRANSCRIPTIONAL PROTEIN ICP0/VMW110
RP   (MICROBIAL INFECTION).
RX   PubMed=16160161; DOI=10.1128/JVI.79.19.12342-12354.2005;
RA   Boutell C., Canning M., Orr A., Everett R.D.;
RT   "Reciprocal activities between herpes simplex virus type 1 regulatory
RT   protein ICP0, a ubiquitin E3 ligase, and ubiquitin-specific protease
RT   USP7.";
RL   J. Virol. 79:12342-12354(2005).
RN   [11]
RP   FUNCTION, IDENTIFICATION IN A COMPLEX WITH DAXX AND MDM2, INTERACTION
RP   WITH DAXX, AND SUBCELLULAR LOCATION.
RX   PubMed=16845383; DOI=10.1038/ncb1442;
RA   Tang J., Qu L.K., Zhang J., Wang W., Michaelson J.S., Degenhardt Y.Y.,
RA   El-Deiry W.S., Yang X.;
RT   "Critical role for Daxx in regulating Mdm2.";
RL   Nat. Cell Biol. 8:855-862(2006).
RN   [12]
RP   FUNCTION, INTERACTION WITH FOXO4, MUTAGENESIS OF CYS-223, AND
RP   CATALYTIC ACTIVITY.
RX   PubMed=16964248; DOI=10.1038/ncb1469;
RA   van der Horst A., de Vries-Smits A.M., Brenkman A.B., van Triest M.H.,
RA   van den Broek N., Colland F., Maurice M.M., Burgering B.M.;
RT   "FOXO4 transcriptional activity is regulated by monoubiquitination and
RT   USP7/HAUSP.";
RL   Nat. Cell Biol. 8:1064-1073(2006).
RN   [13]
RP   SUBUNIT, PHOSPHORYLATION AT SER-18 AND SER-963, UBIQUITINATION AT
RP   LYS-869, SUBCELLULAR LOCATION, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY.
RX   PubMed=17651432; DOI=10.1111/j.1742-4658.2007.05952.x;
RA   Fernandez-Montalvan A., Bouwmeester T., Joberty G., Mader R.,
RA   Mahnke M., Pierrat B., Schlaeppi J.M., Worpenberg S., Gerhartz B.;
RT   "Biochemical characterization of USP7 reveals post-translational
RT   modification sites and structural requirements for substrate
RT   processing and subcellular localization.";
RL   FEBS J. 274:4256-4270(2007).
RN   [14]
RP   FUNCTION, IDENTIFICATION IN A COMPLEX WITH DAXX; RASSF1 AND MDM2, AND
RP   INTERACTION WITH DAXX AND MDM2.
RX   PubMed=18566590; DOI=10.1038/emboj.2008.115;
RA   Song M.S., Song S.J., Kim S.Y., Oh H.J., Lim D.S.;
RT   "The tumour suppressor RASSF1A promotes MDM2 self-ubiquitination by
RT   disrupting the MDM2-DAXX-HAUSP complex.";
RL   EMBO J. 27:1863-1874(2008).
RN   [15]
RP   INTERACTION WITH UBXN6.
RX   PubMed=18768758; DOI=10.1091/mbc.E08-01-0067;
RA   Zweitzig D.R., Shcherbik N., Haines D.S.;
RT   "AAA ATPase p97 and adaptor UBXD1 suppress MDM2 ubiquitination and
RT   degradation and promote constitutive p53 turnover.";
RL   Mol. Biol. Cell 19:5029-5029(2008).
RN   [16]
RP   FUNCTION, CATALYTIC ACTIVITY, INTERACTION WITH PTEN, MUTAGENESIS OF
RP   CYS-223, SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.
RX   PubMed=18716620; DOI=10.1038/nature07290;
RA   Song M.S., Salmena L., Carracedo A., Egia A., Lo-Coco F.,
RA   Teruya-Feldstein J., Pandolfi P.P.;
RT   "The deubiquitinylation and localization of PTEN are regulated by a
RT   HAUSP-PML network.";
RL   Nature 455:813-817(2008).
RN   [17]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-18 AND SER-963, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [18]
RP   FUNCTION (MICROBIAL INFECTION), INTERACTION WITH HERPESVIRUS 1
RP   TRANS-ACTING TRANSCRIPTIONAL PROTEIN ICP0/VMW110 (MICROBIAL
RP   INFECTION), SUBCELLULAR LOCATION, IDENTIFICATION BY MASS SPECTROMETRY,
RP   AND ALTERNATIVE SPLICING (ISOFORM 2).
RX   PubMed=18590780; DOI=10.1016/j.virusres.2008.05.017;
RA   Antrobus R., Boutell C.;
RT   "Identification of a novel higher molecular weight isoform of
RT   USP7/HAUSP that interacts with the Herpes simplex virus type-1
RT   immediate early protein ICP0.";
RL   Virus Res. 137:64-71(2008).
RN   [19]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [20]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-869; LYS-1084 AND LYS-1096,
RP   AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M.,
RA   Walther T.C., Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [21]
RP   FUNCTION.
RX   PubMed=20153724; DOI=10.1016/j.bbrc.2010.02.051;
RA   Tang J., Qu L., Pang M., Yang X.;
RT   "Daxx is reciprocally regulated by Mdm2 and Hausp.";
RL   Biochem. Biophys. Res. Commun. 393:542-545(2010).
RN   [22]
RP   FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH THE PRC1-LIKE
RP   COMPLEX.
RX   PubMed=20601937; DOI=10.1038/emboj.2010.129;
RA   Maertens G.N., El Messaoudi-Aubert S., Elderkin S., Hiom K.,
RA   Peters G.;
RT   "Ubiquitin-specific proteases 7 and 11 modulate Polycomb regulation of
RT   the INK4a tumour suppressor.";
RL   EMBO J. 29:2553-2565(2010).
RN   [23]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-18, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [24]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [25]
RP   INTERACTION WITH TSPYL5.
RX   PubMed=21170034; DOI=10.1038/ncb2142;
RA   Epping M.T., Meijer L.A., Krijgsman O., Bos J.L., Pandolfi P.P.,
RA   Bernards R.;
RT   "TSPYL5 suppresses p53 levels and function by physical interaction
RT   with USP7.";
RL   Nat. Cell Biol. 13:102-108(2011).
RN   [26]
RP   FUNCTION, CATALYTIC ACTIVITY, INTERACTION WITH DNMT1 AND UHRF1,
RP   MUTAGENESIS OF CYS-223, AND ACTIVE SITE.
RX   PubMed=21745816; DOI=10.1093/nar/gkr528;
RA   Felle M., Joppien S., Nemeth A., Diermeier S., Thalhammer V.,
RA   Dobner T., Kremmer E., Kappler R., Langst G.;
RT   "The USP7/Dnmt1 complex stimulates the DNA methylation activity of
RT   Dnmt1 and regulates the stability of UHRF1.";
RL   Nucleic Acids Res. 39:8355-8365(2011).
RN   [27]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-18, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J.,
RA   Johansen P.T., Kratchmarova I., Kassem M., Mann M., Olsen J.V.,
RA   Blagoev B.;
RT   "System-wide temporal characterization of the proteome and
RT   phosphoproteome of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [28]
RP   FUNCTION, CATALYTIC ACTIVITY, INTERACTION WITH UHRF1, MUTAGENESIS OF
RP   CYS-223, AND ACTIVE SITE.
RX   PubMed=22411829; DOI=10.1073/pnas.1116349109;
RA   Ma H., Chen H., Guo X., Wang Z., Sowa M.E., Zheng L., Hu S., Zeng P.,
RA   Guo R., Diao J., Lan F., Harper J.W., Shi Y.G., Xu Y., Shi Y.;
RT   "M phase phosphorylation of the epigenetic regulator UHRF1 regulates
RT   its physical association with the deubiquitylase USP7 and stability.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:4828-4833(2012).
RN   [29]
RP   FUNCTION, AND LINKAGE SPECIFICITY.
RX   PubMed=22689415; DOI=10.1002/cbic.201200261;
RA   Iphofer A., Kummer A., Nimtz M., Ritter A., Arnold T., Frank R.,
RA   van den Heuvel J., Kessler B.M., Jansch L., Franke R.;
RT   "Profiling ubiquitin linkage specificities of deubiquitinating enzymes
RT   with branched ubiquitin isopeptide probes.";
RL   ChemBioChem 13:1416-1420(2012).
RN   [30]
RP   INTERACTION WITH MEX3C.
RX   PubMed=22863774; DOI=10.1038/emboj.2012.218;
RA   Cano F., Bye H., Duncan L.M., Buchet-Poyau K., Billaud M., Wills M.R.,
RA   Lehner P.J.;
RT   "The RNA-binding E3 ubiquitin ligase MEX-3C links ubiquitination with
RT   MHC-I mRNA degradation.";
RL   EMBO J. 31:3596-3606(2012).
RN   [31]
RP   FUNCTION, AND INTERACTION WITH UVSSA.
RX   PubMed=22466611; DOI=10.1038/ng.2230;
RA   Schwertman P., Lagarou A., Dekkers D.H., Raams A., van der Hoek A.C.,
RA   Laffeber C., Hoeijmakers J.H., Demmers J.A., Fousteri M.,
RA   Vermeulen W., Marteijn J.A.;
RT   "UV-sensitive syndrome protein UVSSA recruits USP7 to regulate
RT   transcription-coupled repair.";
RL   Nat. Genet. 44:598-602(2012).
RN   [32]
RP   FUNCTION, AND INTERACTION WITH UVSSA.
RX   PubMed=22466612; DOI=10.1038/ng.2228;
RA   Zhang X., Horibata K., Saijo M., Ishigami C., Ukai A., Kanno S.I.,
RA   Tahara H., Neilan E.G., Honma M., Nohmi T., Yasui A., Tanaka K.;
RT   "Mutations in UVSSA cause UV-sensitive syndrome and destabilize ERCC6
RT   in transcription-coupled DNA repair.";
RL   Nat. Genet. 44:593-597(2012).
RN   [33]
RP   IDENTIFICATION BY MASS SPECTROMETRY, FUNCTION, SUBCELLULAR LOCATION,
RP   INTERACTION WITH FOXP3, AND INDUCTION.
RX   PubMed=23973222; DOI=10.1016/j.immuni.2013.05.018;
RA   van Loosdregt J., Fleskens V., Fu J., Brenkman A.B., Bekker C.P.,
RA   Pals C.E., Meerding J., Berkers C.R., Barbi J., Grone A., Sijts A.J.,
RA   Maurice M.M., Kalkhoven E., Prakken B.J., Ovaa H., Pan F., Zaiss D.M.,
RA   Coffer P.J.;
RT   "Stabilization of the transcription factor Foxp3 by the deubiquitinase
RT   USP7 increases Treg-cell-suppressive capacity.";
RL   Immunity 39:259-271(2013).
RN   [34]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-18, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [35]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-18, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [36]
RP   INTERACTION WITH RNF220.
RX   PubMed=25266658; DOI=10.1128/MCB.00731-14;
RA   Ma P., Yang X., Kong Q., Li C., Yang S., Li Y., Mao B.;
RT   "The ubiquitin ligase RNF220 enhances canonical Wnt signaling through
RT   USP7-mediated deubiquitination of beta-catenin.";
RL   Mol. Cell. Biol. 34:4355-4366(2014).
RN   [37]
RP   FUNCTION, CATALYTIC ACTIVITY, INTERACTION WITH FAM175B AND TP53, AND
RP   SUBCELLULAR LOCATION.
RX   PubMed=25283148; DOI=10.1038/ncomms6059;
RA   Zhang J., Cao M., Dong J., Li C., Xu W., Zhan Y., Wang X., Yu M.,
RA   Ge C., Ge Z., Yang X.;
RT   "ABRO1 suppresses tumourigenesis and regulates the DNA damage response
RT   by stabilizing p53.";
RL   Nat. Commun. 5:5059-5059(2014).
RN   [38]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-869, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25114211; DOI=10.1073/pnas.1413825111;
RA   Impens F., Radoshevich L., Cossart P., Ribet D.;
RT   "Mapping of SUMO sites and analysis of SUMOylation changes induced by
RT   external stimuli.";
RL   Proc. Natl. Acad. Sci. U.S.A. 111:12432-12437(2014).
RN   [39]
RP   X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF 208-560 IN COMPLEX WITH
RP   UBIQUITIN, CATALYTIC ACTIVITY, ACTIVE SITE, MUTAGENESIS OF CYS-223;
RP   HIS-456 AND HIS-464, AND INTERACTION WITH TP53.
RX   PubMed=12507430; DOI=10.1016/S0092-8674(02)01199-6;
RA   Hu M., Li P., Li M., Li W., Yao T., Wu J.-W., Gu W., Cohen R.E.,
RA   Shi Y.;
RT   "Crystal structure of a UBP-family deubiquitinating enzyme in
RT   isolation and in complex with ubiquitin aldehyde.";
RL   Cell 111:1041-1054(2002).
RN   [40]
RP   X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS) OF 54-205 IN COMPLEX WITH EBNA1,
RP   AND INTERACTION WITH EBV EBNA1.
RX   PubMed=15808506; DOI=10.1016/j.molcel.2005.02.029;
RA   Saridakis V., Sheng Y., Sarkari F., Holowaty M.N., Shire K.,
RA   Nguyen T., Zhang R.G., Liao J., Lee W., Edwards A.M., Arrowsmith C.H.,
RA   Frappier L.;
RT   "Structure of the p53 binding domain of HAUSP/USP7 bound to Epstein-
RT   Barr nuclear antigen 1 implications for EBV-mediated
RT   immortalization.";
RL   Mol. Cell 18:25-36(2005).
RN   [41]
RP   X-RAY CRYSTALLOGRAPHY (1.65 ANGSTROMS) OF 43-560 IN COMPLEX WITH TP53
RP   AND MDM2, AND INTERACTION WITH TP53 AND MDM2.
RX   PubMed=16402859; DOI=10.1371/journal.pbio.0040027;
RA   Hu M., Gu L., Li M., Jeffrey P.D., Gu W., Shi Y.;
RT   "Structural basis of competitive recognition of p53 and MDM2 by
RT   HAUSP/USP7: implications for the regulation of the p53-MDM2 pathway.";
RL   PLoS Biol. 4:228-239(2006).
RN   [42]
RP   X-RAY CRYSTALLOGRAPHY (1.6 ANGSTROMS) OF 54-205 IN COMPLEX WITH TP53
RP   AND MDM2, INTERACTION WITH TP53 AND MDM2, AND MUTAGENESIS OF ASP-164
RP   AND TRP-165.
RX   PubMed=16474402; DOI=10.1038/nsmb1067;
RA   Sheng Y., Saridakis V., Sarkari F., Duan S., Wu T., Arrowsmith C.H.,
RA   Frappier L.;
RT   "Molecular recognition of p53 and MDM2 by USP7/HAUSP.";
RL   Nat. Struct. Mol. Biol. 13:285-291(2006).
CC   -!- FUNCTION: Hydrolase that deubiquitinates target proteins such as
CC       FOXO4, p53/TP53, MDM2, ERCC6, DNMT1, UHRF1, PTEN and DAXX
CC       (PubMed:11923872, PubMed:15053880, PubMed:16964248,
CC       PubMed:18716620, PubMed:25283148). Together with DAXX, prevents
CC       MDM2 self-ubiquitination and enhances the E3 ligase activity of
CC       MDM2 towards p53/TP53, thereby promoting p53/TP53 ubiquitination
CC       and proteasomal degradation (PubMed:15053880, PubMed:16845383,
CC       PubMed:18566590, PubMed:20153724). Deubiquitinates p53/TP53,
CC       preventing degradation of p53/TP53, and enhances p53/TP53-
CC       dependent transcription regulation, cell growth repression and
CC       apoptosis (PubMed:25283148). Deubiquitinates p53/TP53 and MDM2 and
CC       strongly stabilizes p53/TP53 even in the presence of excess MDM2,
CC       and also induces p53/TP53-dependent cell growth repression and
CC       apoptosis (PubMed:11923872). Deubiquitination of FOXO4 in presence
CC       of hydrogen peroxide is not dependent on p53/TP53 and inhibits
CC       FOXO4-induced transcriptional activity (PubMed:16964248). In
CC       association with DAXX, is involved in the deubiquitination and
CC       translocation of PTEN from the nucleus to the cytoplasm, both
CC       processes that are counteracted by PML (PubMed:18716620). Involved
CC       in cell proliferation during early embryonic development. Involved
CC       in transcription-coupled nucleotide excision repair (TC-NER) in
CC       response to UV damage: recruited to DNA damage sites following
CC       interaction with KIAA1530/UVSSA and promotes deubiquitination of
CC       ERCC6, preventing UV-induced degradation of ERCC6
CC       (PubMed:22466611, PubMed:22466612). Involved in maintenance of DNA
CC       methylation via its interaction with UHRF1 and DNMT1: acts by
CC       mediating deubiquitination of UHRF1 and DNMT1, preventing their
CC       degradation and promoting DNA methylation by DNMT1
CC       (PubMed:21745816, PubMed:22411829). Acts as a chromatin regulator
CC       via its association with the Polycomb group (PcG) multiprotein
CC       PRC1-like complex; may act by deubiquitinating components of the
CC       PRC1-like complex (PubMed:20601937). Able to mediate
CC       deubiquitination of histone H2B; it is however unsure whether this
CC       activity takes place in vivo (PubMed:20601937). Exhibits a
CC       preference towards 'Lys-48'-linked ubiquitin chains
CC       (PubMed:22689415). Increases regulatory T-cells (Treg) suppressive
CC       capacity by deubiquitinating and stabilizing the transcription
CC       factor FOXP3 which is crucial for Treg cell function
CC       (PubMed:23973222). {ECO:0000269|PubMed:11923872,
CC       ECO:0000269|PubMed:15053880, ECO:0000269|PubMed:16845383,
CC       ECO:0000269|PubMed:16964248, ECO:0000269|PubMed:18566590,
CC       ECO:0000269|PubMed:18716620, ECO:0000269|PubMed:20153724,
CC       ECO:0000269|PubMed:20601937, ECO:0000269|PubMed:21745816,
CC       ECO:0000269|PubMed:22411829, ECO:0000269|PubMed:22466611,
CC       ECO:0000269|PubMed:22466612, ECO:0000269|PubMed:22689415,
CC       ECO:0000269|PubMed:23973222, ECO:0000269|PubMed:25283148}.
CC   -!- FUNCTION: (Microbial infection) Contributes to the overall
CC       stabilization and trans-activation capability of the herpesvirus 1
CC       trans-acting transcriptional protein ICP0/VMW110 during HSV-1
CC       infection. {ECO:0000269|PubMed:14506283,
CC       ECO:0000269|PubMed:16160161, ECO:0000269|PubMed:18590780}.
CC   -!- CATALYTIC ACTIVITY: Thiol-dependent hydrolysis of ester,
CC       thioester, amide, peptide and isopeptide bonds formed by the C-
CC       terminal Gly of ubiquitin (a 76-residue protein attached to
CC       proteins as an intracellular targeting signal).
CC       {ECO:0000269|PubMed:11923872, ECO:0000269|PubMed:12507430,
CC       ECO:0000269|PubMed:14506283, ECO:0000269|PubMed:15053880,
CC       ECO:0000269|PubMed:16964248, ECO:0000269|PubMed:18716620,
CC       ECO:0000269|PubMed:21745816}.
CC   -!- ENZYME REGULATION: Inhibited by N-ethyl-maleimide (NEM) and
CC       divalent cations. Tolerates high concentrations of NaCl but is
CC       inhibited at concentrations of 195 mM and higher.
CC       {ECO:0000269|PubMed:14506283}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       pH dependence:
CC         Active from pH 7.0 to 9.5. {ECO:0000269|PubMed:14506283};
CC   -!- SUBUNIT: Monomer. Homodimer. Part of a complex with DAXX, MDM2,
CC       RASSF1 and USP7 (PubMed:18566590). Part of a complex with DAXX,
CC       MDM2 and USP7 (PubMed:16845383). Interacts with MDM2; the
CC       interaction is independent of p53/TP53. Interacts with DAXX; the
CC       interaction is direct and independent of MDM2 and p53/TP53
CC       (PubMed:16845383). Interacts with FOXO4; the interaction is
CC       enhanced in presence of hydrogen peroxide and occurs independently
CC       of p53/TP53 (PubMed:16964248). Interacts with p53/TP53; the
CC       interaction is enhanced in response to DNA damage
CC       (PubMed:25283148). Interacts with TSPYL5; this impairs interaction
CC       with p53/TP53 (PubMed:21170034). Interacts with PTEN; the
CC       interaction is direct (PubMed:18716620). Interacts with UBXN6
CC       (PubMed:18768758). Interacts with ATXN1 and the strength of
CC       interaction is influenced by the length of the poly-Gln region in
CC       ATXN1. A weaker interaction seen with mutants having longer poly-
CC       Gln regions (PubMed:12093161). Interacts with KIAA1530/UVSSA
CC       (PubMed:22466611, PubMed:22466612). Interacts with FAM175B; the
CC       interaction is direct (PubMed:25283148). Identified in a complex
CC       with TP53/p53 and FAM175B (PubMed:25283148). Interacts with MEX3C
CC       and antagonizes its ability to degrade mRNA (PubMed:22863774).
CC       Interacts with DNMT1 and UHRF1 (PubMed:21745816). Interacts with
CC       FOXP3 (PubMed:23973222). Interacts (via MATH domain) with RNF220
CC       (PubMed:25266658). Associated component of the Polycomb group
CC       (PcG) multiprotein PRC1-like complex (PubMed:20601937). Interacts
CC       with EPOP (By similarity). {ECO:0000250|UniProtKB:Q6A4J8,
CC       ECO:0000269|PubMed:11923872, ECO:0000269|PubMed:12093161,
CC       ECO:0000269|PubMed:12507430, ECO:0000269|PubMed:14506283,
CC       ECO:0000269|PubMed:15053880, ECO:0000269|PubMed:15808506,
CC       ECO:0000269|PubMed:16402859, ECO:0000269|PubMed:16474402,
CC       ECO:0000269|PubMed:16845383, ECO:0000269|PubMed:16964248,
CC       ECO:0000269|PubMed:17651432, ECO:0000269|PubMed:18566590,
CC       ECO:0000269|PubMed:18716620, ECO:0000269|PubMed:18768758,
CC       ECO:0000269|PubMed:20601937, ECO:0000269|PubMed:21170034,
CC       ECO:0000269|PubMed:21745816, ECO:0000269|PubMed:22411829,
CC       ECO:0000269|PubMed:22466611, ECO:0000269|PubMed:22466612,
CC       ECO:0000269|PubMed:22863774, ECO:0000269|PubMed:23973222,
CC       ECO:0000269|PubMed:25266658, ECO:0000269|PubMed:25283148}.
CC   -!- SUBUNIT: (Microbial infection) Isoform 1 and isoform 2 interact
CC       with herpesvirus 1 trans-acting transcriptional protein
CC       ICP0/VMW110 (PubMed:9034339, PubMed:14506283, PubMed:16160161,
CC       PubMed:18590780). Interacts with Epstein-Barr virus EBNA1
CC       (PubMed:14506283). EBNA1 shows a 10-fold higher affinity than
CC       p53/TP53 and can compete with it for USP7 binding
CC       (PubMed:14506283). Binding to ICP0/VMW110 may modulate the
CC       substrate specificity or activity of USP7 to stabilize viral
CC       proteins. {ECO:0000269|PubMed:14506283,
CC       ECO:0000269|PubMed:16160161, ECO:0000269|PubMed:18590780,
CC       ECO:0000269|PubMed:9034339}.
CC   -!- INTERACTION:
CC       Q6W2J9:BCOR; NbExp=3; IntAct=EBI-302474, EBI-950027;
CC       P35226:BMI1; NbExp=7; IntAct=EBI-302474, EBI-2341576;
CC       Q9HC52:CBX8; NbExp=7; IntAct=EBI-302474, EBI-712912;
CC       Q9UER7:DAXX; NbExp=13; IntAct=EBI-302474, EBI-77321;
CC       P03211:EBNA1 (xeno); NbExp=5; IntAct=EBI-302474, EBI-996522;
CC       P21145:MAL; NbExp=3; IntAct=EBI-302474, EBI-3932027;
CC       Q00987:MDM2; NbExp=18; IntAct=EBI-302474, EBI-389668;
CC       O15151:MDM4; NbExp=15; IntAct=EBI-302474, EBI-398437;
CC       O35618:Mdm4 (xeno); NbExp=4; IntAct=EBI-302474, EBI-2603376;
CC       Q5U5Q3:MEX3C; NbExp=3; IntAct=EBI-302474, EBI-2864451;
CC       Q99836:MYD88; NbExp=3; IntAct=EBI-302474, EBI-447677;
CC       P35227:PCGF2; NbExp=5; IntAct=EBI-302474, EBI-2129767;
CC       P06400:RB1; NbExp=8; IntAct=EBI-302474, EBI-491274;
CC       Q06587:RING1; NbExp=5; IntAct=EBI-302474, EBI-752313;
CC       Q99496:RNF2; NbExp=5; IntAct=EBI-302474, EBI-722416;
CC       P84022:SMAD3; NbExp=2; IntAct=EBI-302474, EBI-347161;
CC       Q99426:TBCB; NbExp=2; IntAct=EBI-302474, EBI-764356;
CC       P04637:TP53; NbExp=17; IntAct=EBI-302474, EBI-366083;
CC       Q86VY4:TSPYL5; NbExp=4; IntAct=EBI-302474, EBI-3436472;
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:23973222,
CC       ECO:0000269|PubMed:25283148}. Cytoplasm
CC       {ECO:0000269|PubMed:25283148}. Nucleus, PML body
CC       {ECO:0000269|PubMed:9034339}. Chromosome
CC       {ECO:0000269|PubMed:20601937}. Note=Present in a minority of ND10
CC       nuclear bodies. Association with ICP0/VMW110 at early times of
CC       infection leads to an increased proportion of USP7-containing
CC       ND10. Colocalizes with ATXN1 in the nucleus. Colocalized with DAXX
CC       in speckled structures. Colocalized with PML and PTEN in
CC       promyelocytic leukemia protein (PML) nuclear bodies.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=Q93009-1; Sequence=Displayed;
CC       Name=2; Synonyms=USP7 beta;
CC         IsoId=Q93009-2; Sequence=Not described;
CC         Note=No experimental confirmation available.;
CC       Name=3;
CC         IsoId=Q93009-3; Sequence=VSP_054884;
CC         Note=No experimental confirmation available.;
CC   -!- TISSUE SPECIFICITY: Widely expressed. Overexpressed in prostate
CC       cancer. {ECO:0000269|PubMed:18716620}.
CC   -!- INDUCTION: Up-regulated in regulatory T-cells (Treg).
CC       {ECO:0000269|PubMed:23973222}.
CC   -!- DOMAIN: The C-terminus plays a role in its oligomerization.
CC       {ECO:0000250}.
CC   -!- PTM: Isoform 1: Phosphorylated. Isoform 1 is phosphorylated at
CC       positions Ser-18 and Ser-963. Isoform 2: Not phosphorylated.
CC       {ECO:0000269|PubMed:17651432}.
CC   -!- PTM: Isoform 1: Polyneddylated. Isoform 2: Not Polyneddylated.
CC   -!- PTM: Isoform 1 and isoform 2: Not sumoylated.
CC   -!- PTM: Isoform 1 and isoform 2: Polyubiquitinated by herpesvirus 1
CC       trans-acting transcriptional protein ICP0/VMW110; leading to its
CC       subsequent proteasomal degradation. Isoform 1: Ubiquitinated at
CC       Lys-869. {ECO:0000269|PubMed:16160161,
CC       ECO:0000269|PubMed:17651432}.
CC   -!- SIMILARITY: Belongs to the peptidase C19 family. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/USP7ID42773ch16p13.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; Z72499; CAA96580.1; -; mRNA.
DR   EMBL; AK302771; BAH13801.1; -; mRNA.
DR   EMBL; AC022167; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471112; EAW85194.1; -; Genomic_DNA.
DR   CCDS; CCDS32385.1; -. [Q93009-1]
DR   CCDS; CCDS66941.1; -. [Q93009-3]
DR   RefSeq; NP_001308787.1; NM_001321858.1.
DR   RefSeq; NP_003461.2; NM_003470.2. [Q93009-1]
DR   UniGene; Hs.386939; -.
DR   PDB; 1NB8; X-ray; 2.30 A; A/B=208-560.
DR   PDB; 1NBF; X-ray; 2.30 A; A/B/E=208-560.
DR   PDB; 1YY6; X-ray; 1.70 A; A=54-204.
DR   PDB; 1YZE; X-ray; 2.00 A; A/B/C=54-205.
DR   PDB; 2F1W; X-ray; 1.65 A; A=53-206.
DR   PDB; 2F1X; X-ray; 2.30 A; A/B=53-200.
DR   PDB; 2F1Y; X-ray; 1.70 A; A=53-198.
DR   PDB; 2F1Z; X-ray; 3.20 A; A/B=43-560.
DR   PDB; 2FOJ; X-ray; 1.60 A; A=54-205.
DR   PDB; 2FOO; X-ray; 2.20 A; A=54-205.
DR   PDB; 2FOP; X-ray; 2.10 A; A=54-205.
DR   PDB; 2KVR; NMR; -; A=537-664.
DR   PDB; 2XXN; X-ray; 1.60 A; A=63-205.
DR   PDB; 2YLM; X-ray; 2.70 A; A=560-1084.
DR   PDB; 3MQR; X-ray; 1.80 A; A=54-205.
DR   PDB; 3MQS; X-ray; 2.40 A; C=54-205.
DR   PDB; 4JJQ; X-ray; 1.95 A; A=54-205.
DR   PDB; 4KG9; X-ray; 1.70 A; A=54-205.
DR   PDB; 4M5W; X-ray; 2.24 A; A=207-560.
DR   PDB; 4M5X; X-ray; 2.19 A; A/B=207-560.
DR   PDB; 4PYZ; X-ray; 2.84 A; A/B=537-793.
DR   PDB; 4WPH; X-ray; 2.92 A; A/B=535-888.
DR   PDB; 4WPI; X-ray; 3.40 A; A/B=535-888.
DR   PDB; 4YOC; X-ray; 2.92 A; C=560-1102.
DR   PDB; 4YSI; X-ray; 1.02 A; A=63-205.
DR   PDB; 4Z96; X-ray; 2.85 A; A=560-1083.
DR   PDB; 4Z97; X-ray; 3.00 A; A=560-1083.
DR   PDB; 5C56; X-ray; 2.69 A; A=560-1102.
DR   PDB; 5C6D; X-ray; 2.29 A; A/B=561-881.
DR   PDB; 5FWI; X-ray; 3.40 A; C=207-882.
DR   PDB; 5GG4; X-ray; 3.11 A; A/B/C/D=560-890.
DR   PDB; 5J7T; X-ray; 3.20 A; A=211-881.
DR   PDB; 5JTJ; X-ray; 3.32 A; A=209-554, A=1084-1102.
DR   PDB; 5JTV; X-ray; 3.31 A; A/C/E/G=207-554, A/C/E/G=882-1102.
DR   PDBsum; 1NB8; -.
DR   PDBsum; 1NBF; -.
DR   PDBsum; 1YY6; -.
DR   PDBsum; 1YZE; -.
DR   PDBsum; 2F1W; -.
DR   PDBsum; 2F1X; -.
DR   PDBsum; 2F1Y; -.
DR   PDBsum; 2F1Z; -.
DR   PDBsum; 2FOJ; -.
DR   PDBsum; 2FOO; -.
DR   PDBsum; 2FOP; -.
DR   PDBsum; 2KVR; -.
DR   PDBsum; 2XXN; -.
DR   PDBsum; 2YLM; -.
DR   PDBsum; 3MQR; -.
DR   PDBsum; 3MQS; -.
DR   PDBsum; 4JJQ; -.
DR   PDBsum; 4KG9; -.
DR   PDBsum; 4M5W; -.
DR   PDBsum; 4M5X; -.
DR   PDBsum; 4PYZ; -.
DR   PDBsum; 4WPH; -.
DR   PDBsum; 4WPI; -.
DR   PDBsum; 4YOC; -.
DR   PDBsum; 4YSI; -.
DR   PDBsum; 4Z96; -.
DR   PDBsum; 4Z97; -.
DR   PDBsum; 5C56; -.
DR   PDBsum; 5C6D; -.
DR   PDBsum; 5FWI; -.
DR   PDBsum; 5GG4; -.
DR   PDBsum; 5J7T; -.
DR   PDBsum; 5JTJ; -.
DR   PDBsum; 5JTV; -.
DR   DisProt; DP00941; -.
DR   ProteinModelPortal; Q93009; -.
DR   SMR; Q93009; -.
DR   BioGrid; 113622; 330.
DR   DIP; DIP-29053N; -.
DR   IntAct; Q93009; 145.
DR   MINT; MINT-234628; -.
DR   STRING; 9606.ENSP00000343535; -.
DR   BindingDB; Q93009; -.
DR   ChEMBL; CHEMBL2157850; -.
DR   MEROPS; C19.016; -.
DR   iPTMnet; Q93009; -.
DR   PhosphoSitePlus; Q93009; -.
DR   BioMuta; USP7; -.
DR   DMDM; 212276477; -.
DR   EPD; Q93009; -.
DR   PaxDb; Q93009; -.
DR   PeptideAtlas; Q93009; -.
DR   PRIDE; Q93009; -.
DR   DNASU; 7874; -.
DR   Ensembl; ENST00000344836; ENSP00000343535; ENSG00000187555. [Q93009-1]
DR   Ensembl; ENST00000381886; ENSP00000371310; ENSG00000187555. [Q93009-3]
DR   GeneID; 7874; -.
DR   KEGG; hsa:7874; -.
DR   UCSC; uc002czk.4; human. [Q93009-1]
DR   CTD; 7874; -.
DR   DisGeNET; 7874; -.
DR   GeneCards; USP7; -.
DR   H-InvDB; HIX0038590; -.
DR   HGNC; HGNC:12630; USP7.
DR   HPA; CAB008108; -.
DR   HPA; HPA015641; -.
DR   MIM; 602519; gene.
DR   neXtProt; NX_Q93009; -.
DR   OpenTargets; ENSG00000187555; -.
DR   PharmGKB; PA37255; -.
DR   eggNOG; KOG1863; Eukaryota.
DR   eggNOG; COG5077; LUCA.
DR   GeneTree; ENSGT00760000119158; -.
DR   HOGENOM; HOG000160240; -.
DR   HOVERGEN; HBG018029; -.
DR   InParanoid; Q93009; -.
DR   KO; K11838; -.
DR   OMA; VAMSDGH; -.
DR   OrthoDB; EOG091G01BK; -.
DR   PhylomeDB; Q93009; -.
DR   TreeFam; TF105667; -.
DR   Reactome; R-HSA-5689880; Ub-specific processing proteases.
DR   Reactome; R-HSA-6781823; Formation of TC-NER Pre-Incision Complex.
DR   Reactome; R-HSA-6781827; Transcription-Coupled Nucleotide Excision Repair (TC-NER).
DR   Reactome; R-HSA-6782135; Dual incision in TC-NER.
DR   Reactome; R-HSA-6782210; Gap-filling DNA repair synthesis and ligation in TC-NER.
DR   Reactome; R-HSA-6804757; Regulation of TP53 Degradation.
DR   Reactome; R-HSA-8866652; Synthesis of active ubiquitin: roles of E1 and E2 enzymes.
DR   SignaLink; Q93009; -.
DR   SIGNOR; Q93009; -.
DR   ChiTaRS; USP7; human.
DR   EvolutionaryTrace; Q93009; -.
DR   GeneWiki; USP7; -.
DR   GenomeRNAi; 7874; -.
DR   PRO; PR:Q93009; -.
DR   Proteomes; UP000005640; Chromosome 16.
DR   Bgee; ENSG00000187555; -.
DR   CleanEx; HS_USP7; -.
DR   ExpressionAtlas; Q93009; baseline and differential.
DR   Genevisible; Q93009; HS.
DR   GO; GO:0005694; C:chromosome; IEA:UniProtKB-SubCell.
DR   GO; GO:0005829; C:cytosol; IDA:UniProtKB.
DR   GO; GO:0016604; C:nuclear body; IDA:UniProtKB.
DR   GO; GO:0005654; C:nucleoplasm; TAS:Reactome.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0016605; C:PML body; IEA:UniProtKB-SubCell.
DR   GO; GO:0004197; F:cysteine-type endopeptidase activity; IMP:UniProtKB.
DR   GO; GO:0002039; F:p53 binding; IDA:UniProtKB.
DR   GO; GO:0008022; F:protein C-terminus binding; IPI:UniProtKB.
DR   GO; GO:0004843; F:thiol-dependent ubiquitin-specific protease activity; IDA:UniProtKB.
DR   GO; GO:0036459; F:thiol-dependent ubiquitinyl hydrolase activity; TAS:Reactome.
DR   GO; GO:0008134; F:transcription factor binding; IPI:UniProtKB.
DR   GO; GO:0031625; F:ubiquitin protein ligase binding; IPI:UniProtKB.
DR   GO; GO:0035616; P:histone H2B conserved C-terminal lysine deubiquitination; ISS:UniProtKB.
DR   GO; GO:0010216; P:maintenance of DNA methylation; IMP:UniProtKB.
DR   GO; GO:0035520; P:monoubiquitinated protein deubiquitination; IDA:MGI.
DR   GO; GO:0007275; P:multicellular organism development; IEA:UniProtKB-KW.
DR   GO; GO:0032088; P:negative regulation of NF-kappaB transcription factor activity; IDA:UniProtKB.
DR   GO; GO:0016579; P:protein deubiquitination; IDA:UniProtKB.
DR   GO; GO:0050821; P:protein stabilization; IDA:BHF-UCL.
DR   GO; GO:0016567; P:protein ubiquitination; TAS:Reactome.
DR   GO; GO:0051090; P:regulation of sequence-specific DNA binding transcription factor activity; IDA:UniProtKB.
DR   GO; GO:1904353; P:regulation of telomere capping; TAS:BHF-UCL.
DR   GO; GO:0006283; P:transcription-coupled nucleotide-excision repair; IMP:UniProtKB.
DR   GO; GO:0006511; P:ubiquitin-dependent protein catabolic process; IEA:InterPro.
DR   GO; GO:0016032; P:viral process; IEA:UniProtKB-KW.
DR   Gene3D; 2.60.210.10; -; 1.
DR   InterPro; IPR002083; MATH/TRAF_dom.
DR   InterPro; IPR001394; Peptidase_C19_UCH.
DR   InterPro; IPR008974; TRAF-like.
DR   InterPro; IPR024729; USP7_ICP0-binding_dom.
DR   InterPro; IPR029346; USP_C.
DR   InterPro; IPR018200; USP_CS.
DR   InterPro; IPR028889; USP_dom.
DR   Pfam; PF00917; MATH; 1.
DR   Pfam; PF00443; UCH; 1.
DR   Pfam; PF14533; USP7_C2; 1.
DR   Pfam; PF12436; USP7_ICP0_bdg; 1.
DR   SMART; SM00061; MATH; 1.
DR   SUPFAM; SSF49599; SSF49599; 1.
DR   PROSITE; PS50144; MATH; 1.
DR   PROSITE; PS00972; USP_1; 1.
DR   PROSITE; PS00973; USP_2; 1.
DR   PROSITE; PS50235; USP_3; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; Chromosome;
KW   Complete proteome; Cytoplasm; Developmental protein;
KW   Direct protein sequencing; DNA damage; DNA repair;
KW   Host-virus interaction; Hydrolase; Isopeptide bond; Nucleus;
KW   Phosphoprotein; Protease; Reference proteome; Thiol protease;
KW   Ubl conjugation; Ubl conjugation pathway.
FT   CHAIN         1   1102       Ubiquitin carboxyl-terminal hydrolase 7.
FT                                /FTId=PRO_0000080626.
FT   DOMAIN       68    195       MATH. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00129}.
FT   DOMAIN      214    521       USP.
FT   REGION        1    208       Interaction with TSPYL5.
FT                                {ECO:0000269|PubMed:21170034}.
FT   REGION       53    208       Interaction with p53/TP53, MDM2 and
FT                                EBNA1. {ECO:0000269|PubMed:14506283}.
FT   REGION       70    205       Necessary for nuclear localization.
FT   REGION      622    801       Interaction with ICP0/VMW110.
FT                                {ECO:0000269|PubMed:16160161}.
FT   COMPBIAS      4     10       Poly-Gln.
FT   ACT_SITE    223    223       Nucleophile.
FT                                {ECO:0000269|PubMed:12507430,
FT                                ECO:0000305|PubMed:11923872,
FT                                ECO:0000305|PubMed:15053880,
FT                                ECO:0000305|PubMed:16964248,
FT                                ECO:0000305|PubMed:18716620,
FT                                ECO:0000305|PubMed:21745816,
FT                                ECO:0000305|PubMed:22411829}.
FT   ACT_SITE    464    464       Proton acceptor.
FT                                {ECO:0000305|PubMed:12507430}.
FT   MOD_RES      18     18       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:21406692,
FT                                ECO:0000244|PubMed:23186163,
FT                                ECO:0000244|PubMed:24275569,
FT                                ECO:0000269|PubMed:17651432}.
FT   MOD_RES      49     49       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q6A4J8}.
FT   MOD_RES     869    869       N6-acetyllysine; alternate.
FT                                {ECO:0000244|PubMed:19608861}.
FT   MOD_RES     963    963       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000269|PubMed:17651432}.
FT   MOD_RES    1084   1084       N6-acetyllysine.
FT                                {ECO:0000244|PubMed:19608861}.
FT   MOD_RES    1096   1096       N6-acetyllysine.
FT                                {ECO:0000244|PubMed:19608861}.
FT   CROSSLNK    869    869       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO2);
FT                                alternate. {ECO:0000244|PubMed:25114211}.
FT   CROSSLNK    869    869       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in ubiquitin);
FT                                alternate. {ECO:0000269|PubMed:17651432}.
FT   VAR_SEQ       1     25       MNHQQQQQQQKAGEQQLSEPEDMEM -> MAGNHRLGL
FT                                (in isoform 3).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_054884.
FT   MUTAGEN     164    164       D->A: Decreased binding to p53/TP53 and
FT                                MDM2. {ECO:0000269|PubMed:16474402}.
FT   MUTAGEN     165    165       W->A: Loss of binding to p53/TP53 and
FT                                MDM2. {ECO:0000269|PubMed:16474402}.
FT   MUTAGEN     223    223       C->A: Complete loss of activity.
FT                                Localized in the nucleus and does not
FT                                inhibit FOXO4-dependent transcriptional
FT                                activity. {ECO:0000269|PubMed:11923872,
FT                                ECO:0000269|PubMed:12507430,
FT                                ECO:0000269|PubMed:15053880,
FT                                ECO:0000269|PubMed:16964248,
FT                                ECO:0000269|PubMed:18716620,
FT                                ECO:0000269|PubMed:21745816,
FT                                ECO:0000269|PubMed:22411829}.
FT   MUTAGEN     223    223       C->S: No effect on p53/TP53 and PTEN
FT                                binding but is defective in
FT                                deubiquitinating p53/TP53 and PTEN.
FT                                {ECO:0000269|PubMed:11923872,
FT                                ECO:0000269|PubMed:12507430,
FT                                ECO:0000269|PubMed:15053880,
FT                                ECO:0000269|PubMed:16964248,
FT                                ECO:0000269|PubMed:18716620,
FT                                ECO:0000269|PubMed:21745816,
FT                                ECO:0000269|PubMed:22411829}.
FT   MUTAGEN     456    456       H->A: Complete loss of activity.
FT                                {ECO:0000269|PubMed:12507430}.
FT   MUTAGEN     464    464       H->A: Complete loss of activity.
FT                                {ECO:0000269|PubMed:12507430}.
FT   CONFLICT    201    201       H -> I (in Ref. 1; AA sequence).
FT                                {ECO:0000305}.
FT   CONFLICT    205    205       W -> P (in Ref. 1; AA sequence).
FT                                {ECO:0000305}.
FT   CONFLICT    207    207       S -> Q (in Ref. 1; AA sequence).
FT                                {ECO:0000305}.
FT   CONFLICT   1045   1045       M -> T (in Ref. 1; CAA96580).
FT                                {ECO:0000305}.
FT   CONFLICT   1066   1066       Q -> T (in Ref. 1; AA sequence).
FT                                {ECO:0000305}.
FT   STRAND       67     77       {ECO:0000244|PDB:4YSI}.
FT   HELIX        78     80       {ECO:0000244|PDB:4YSI}.
FT   STRAND       90     92       {ECO:0000244|PDB:4YSI}.
FT   STRAND       95    105       {ECO:0000244|PDB:4YSI}.
FT   STRAND      106    110       {ECO:0000244|PDB:2F1X}.
FT   STRAND      113    122       {ECO:0000244|PDB:4YSI}.
FT   STRAND      131    140       {ECO:0000244|PDB:4YSI}.
FT   HELIX       146    148       {ECO:0000244|PDB:4YSI}.
FT   STRAND      150    159       {ECO:0000244|PDB:4YSI}.
FT   HELIX       160    162       {ECO:0000244|PDB:2F1Z}.
FT   STRAND      164    172       {ECO:0000244|PDB:4YSI}.
FT   HELIX       173    176       {ECO:0000244|PDB:4YSI}.
FT   TURN        179    181       {ECO:0000244|PDB:4YSI}.
FT   STRAND      182    185       {ECO:0000244|PDB:2XXN}.
FT   STRAND      188    197       {ECO:0000244|PDB:4YSI}.
FT   STRAND      201    203       {ECO:0000244|PDB:4YSI}.
FT   TURN        209    211       {ECO:0000244|PDB:4M5W}.
FT   TURN        221    224       {ECO:0000244|PDB:1NB8}.
FT   HELIX       225    233       {ECO:0000244|PDB:4M5X}.
FT   HELIX       236    244       {ECO:0000244|PDB:4M5X}.
FT   STRAND      248    250       {ECO:0000244|PDB:5J7T}.
FT   TURN        252    254       {ECO:0000244|PDB:4M5X}.
FT   HELIX       256    269       {ECO:0000244|PDB:4M5X}.
FT   HELIX       277    283       {ECO:0000244|PDB:4M5X}.
FT   TURN        288    293       {ECO:0000244|PDB:4M5X}.
FT   HELIX       296    311       {ECO:0000244|PDB:4M5X}.
FT   TURN        315    318       {ECO:0000244|PDB:4M5X}.
FT   HELIX       319    324       {ECO:0000244|PDB:4M5X}.
FT   STRAND      326    338       {ECO:0000244|PDB:4M5X}.
FT   STRAND      340    352       {ECO:0000244|PDB:4M5X}.
FT   HELIX       360    367       {ECO:0000244|PDB:4M5X}.
FT   STRAND      371    373       {ECO:0000244|PDB:4M5X}.
FT   HELIX       375    377       {ECO:0000244|PDB:4M5X}.
FT   HELIX       382    384       {ECO:0000244|PDB:4M5X}.
FT   STRAND      385    387       {ECO:0000244|PDB:5J7T}.
FT   STRAND      389    397       {ECO:0000244|PDB:4M5X}.
FT   STRAND      400    406       {ECO:0000244|PDB:4M5X}.
FT   STRAND      409    412       {ECO:0000244|PDB:1NBF}.
FT   TURN        413    415       {ECO:0000244|PDB:4M5X}.
FT   STRAND      417    420       {ECO:0000244|PDB:1NBF}.
FT   STRAND      429    432       {ECO:0000244|PDB:4M5X}.
FT   HELIX       434    436       {ECO:0000244|PDB:4M5X}.
FT   STRAND      437    439       {ECO:0000244|PDB:4M5X}.
FT   STRAND      442    444       {ECO:0000244|PDB:4M5W}.
FT   STRAND      447    458       {ECO:0000244|PDB:4M5X}.
FT   STRAND      460    462       {ECO:0000244|PDB:4M5X}.
FT   STRAND      464    469       {ECO:0000244|PDB:4M5X}.
FT   STRAND      473    475       {ECO:0000244|PDB:4M5X}.
FT   STRAND      477    481       {ECO:0000244|PDB:4M5X}.
FT   STRAND      484    488       {ECO:0000244|PDB:4M5X}.
FT   HELIX       490    493       {ECO:0000244|PDB:4M5X}.
FT   HELIX       495    497       {ECO:0000244|PDB:4M5X}.
FT   TURN        504    506       {ECO:0000244|PDB:5J7T}.
FT   TURN        507    510       {ECO:0000244|PDB:1NBF}.
FT   STRAND      511    520       {ECO:0000244|PDB:4M5X}.
FT   HELIX       521    523       {ECO:0000244|PDB:4M5X}.
FT   HELIX       524    527       {ECO:0000244|PDB:4M5X}.
FT   HELIX       533    535       {ECO:0000244|PDB:4M5X}.
FT   HELIX       538    551       {ECO:0000244|PDB:4M5X}.
FT   HELIX       561    563       {ECO:0000244|PDB:5C56}.
FT   STRAND      564    570       {ECO:0000244|PDB:5C6D}.
FT   HELIX       572    574       {ECO:0000244|PDB:5C6D}.
FT   TURN        575    577       {ECO:0000244|PDB:5C6D}.
FT   STRAND      580    584       {ECO:0000244|PDB:5C6D}.
FT   STRAND      588    597       {ECO:0000244|PDB:5C6D}.
FT   HELIX       602    613       {ECO:0000244|PDB:5C6D}.
FT   HELIX       617    619       {ECO:0000244|PDB:5C6D}.
FT   STRAND      620    628       {ECO:0000244|PDB:5C6D}.
FT   TURN        629    631       {ECO:0000244|PDB:5C56}.
FT   STRAND      633    635       {ECO:0000244|PDB:5C6D}.
FT   HELIX       640    643       {ECO:0000244|PDB:2YLM}.
FT   STRAND      645    647       {ECO:0000244|PDB:5C6D}.
FT   HELIX       648    651       {ECO:0000244|PDB:5C6D}.
FT   TURN        652    654       {ECO:0000244|PDB:5C6D}.
FT   STRAND      656    664       {ECO:0000244|PDB:5C6D}.
FT   HELIX       668    671       {ECO:0000244|PDB:5C56}.
FT   TURN        681    683       {ECO:0000244|PDB:5C6D}.
FT   STRAND      684    693       {ECO:0000244|PDB:5C6D}.
FT   TURN        694    697       {ECO:0000244|PDB:5C6D}.
FT   STRAND      698    708       {ECO:0000244|PDB:5C6D}.
FT   HELIX       714    716       {ECO:0000244|PDB:5C6D}.
FT   HELIX       717    724       {ECO:0000244|PDB:5C6D}.
FT   STRAND      732    739       {ECO:0000244|PDB:5C6D}.
FT   STRAND      742    745       {ECO:0000244|PDB:5C6D}.
FT   STRAND      749    752       {ECO:0000244|PDB:2YLM}.
FT   HELIX       753    756       {ECO:0000244|PDB:5C6D}.
FT   STRAND      757    759       {ECO:0000244|PDB:5C56}.
FT   STRAND      764    770       {ECO:0000244|PDB:5C6D}.
FT   HELIX       773    777       {ECO:0000244|PDB:5C6D}.
FT   STRAND      778    780       {ECO:0000244|PDB:5C6D}.
FT   HELIX       783    792       {ECO:0000244|PDB:5C6D}.
FT   STRAND      793    800       {ECO:0000244|PDB:5C6D}.
FT   STRAND      803    805       {ECO:0000244|PDB:4Z96}.
FT   STRAND      809    814       {ECO:0000244|PDB:5C6D}.
FT   HELIX       819    829       {ECO:0000244|PDB:5C6D}.
FT   HELIX       834    836       {ECO:0000244|PDB:5C6D}.
FT   STRAND      837    840       {ECO:0000244|PDB:5C6D}.
FT   STRAND      846    848       {ECO:0000244|PDB:5C6D}.
FT   HELIX       861    865       {ECO:0000244|PDB:5C6D}.
FT   STRAND      866    868       {ECO:0000244|PDB:5J7T}.
FT   STRAND      870    872       {ECO:0000244|PDB:5C6D}.
FT   STRAND      875    880       {ECO:0000244|PDB:5C6D}.
FT   HELIX       885    890       {ECO:0000244|PDB:5C56}.
FT   STRAND      894    899       {ECO:0000244|PDB:5C56}.
FT   STRAND      905    910       {ECO:0000244|PDB:5C56}.
FT   HELIX       918    928       {ECO:0000244|PDB:5C56}.
FT   STRAND      933    935       {ECO:0000244|PDB:4YOC}.
FT   STRAND      939    945       {ECO:0000244|PDB:5C56}.
FT   STRAND      948    953       {ECO:0000244|PDB:5C56}.
FT   HELIX       959    961       {ECO:0000244|PDB:5C56}.
FT   STRAND      969    974       {ECO:0000244|PDB:5C56}.
FT   HELIX       977    979       {ECO:0000244|PDB:5C56}.
FT   TURN        984    986       {ECO:0000244|PDB:5C56}.
FT   STRAND      987    998       {ECO:0000244|PDB:5C56}.
FT   STRAND     1003   1014       {ECO:0000244|PDB:5C56}.
FT   HELIX      1017   1027       {ECO:0000244|PDB:5C56}.
FT   HELIX      1032   1035       {ECO:0000244|PDB:5C56}.
FT   STRAND     1039   1044       {ECO:0000244|PDB:5C56}.
FT   STRAND     1047   1050       {ECO:0000244|PDB:5C56}.
FT   TURN       1053   1055       {ECO:0000244|PDB:5C56}.
FT   HELIX      1060   1062       {ECO:0000244|PDB:5C56}.
FT   STRAND     1070   1072       {ECO:0000244|PDB:2YLM}.
FT   STRAND     1076   1080       {ECO:0000244|PDB:5C56}.
SQ   SEQUENCE   1102 AA;  128302 MW;  F1A5A5C421396E45 CRC64;
     MNHQQQQQQQ KAGEQQLSEP EDMEMEAGDT DDPPRITQNP VINGNVALSD GHNTAEEDME
     DDTSWRSEAT FQFTVERFSR LSESVLSPPC FVRNLPWKIM VMPRFYPDRP HQKSVGFFLQ
     CNAESDSTSW SCHAQAVLKI INYRDDEKSF SRRISHLFFH KENDWGFSNF MAWSEVTDPE
     KGFIDDDKVT FEVFVQADAP HGVAWDSKKH TGYVGLKNQG ATCYMNSLLQ TLFFTNQLRK
     AVYMMPTEGD DSSKSVPLAL QRVFYELQHS DKPVGTKKLT KSFGWETLDS FMQHDVQELC
     RVLLDNVENK MKGTCVEGTI PKLFRGKMVS YIQCKEVDYR SDRREDYYDI QLSIKGKKNI
     FESFVDYVAV EQLDGDNKYD AGEHGLQEAE KGVKFLTLPP VLHLQLMRFM YDPQTDQNIK
     INDRFEFPEQ LPLDEFLQKT DPKDPANYIL HAVLVHSGDN HGGHYVVYLN PKGDGKWCKF
     DDDVVSRCTK EEAIEHNYGG HDDDLSVRHC TNAYMLVYIR ESKLSEVLQA VTDHDIPQQL
     VERLQEEKRI EAQKRKERQE AHLYMQVQIV AEDQFCGHQG NDMYDEEKVK YTVFKVLKNS
     SLAEFVQSLS QTMGFPQDQI RLWPMQARSN GTKRPAMLDN EADGNKTMIE LSDNENPWTI
     FLETVDPELA ASGATLPKFD KDHDVMLFLK MYDPKTRSLN YCGHIYTPIS CKIRDLLPVM
     CDRAGFIQDT SLILYEEVKP NLTERIQDYD VSLDKALDEL MDGDIIVFQK DDPENDNSEL
     PTAKEYFRDL YHRVDVIFCD KTIPNDPGFV VTLSNRMNYF QVAKTVAQRL NTDPMLLQFF
     KSQGYRDGPG NPLRHNYEGT LRDLLQFFKP RQPKKLYYQQ LKMKITDFEN RRSFKCIWLN
     SQFREEEITL YPDKHGCVRD LLEECKKAVE LGEKASGKLR LLEIVSYKII GVHQEDELLE
     CLSPATSRTF RIEEIPLDQV DIDKENEMLV TVAHFHKEVF GTFGIPFLLR IHQGEHFREV
     MKRIQSLLDI QEKEFEKFKF AIVMMGRHQY INEDEYEVNL KDFEPQPGNM SHPRPWLGLD
     HFNKAPKRSR YTYLEKAIKI HN
//
